Outlook on the Cardiovascular Drugs Global Market to 2026 - Advancement in R&D for Effective Drugs Presents Opportunities - ResearchAndMarkets.com

·3 min read

DUBLIN, January 21, 2022--(BUSINESS WIRE)--The "Global Cardiovascular Drugs Market (2021-2026) by Drug Type, Disease Indications, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Cardiovascular Drugs Market is estimated to be USD 78.96 Bn in 2021 and is expected to reach USD 96.99 Bn by 2026, growing at a CAGR of 4.2%.

According to WHO, around 17.9 million people died from cardiovascular diseases in 2019. Cardiovascular diseases are rising owing to increasingly sedentary lifestyles and unhealthy diets. Additionally, the rising geriatric population has further increased the incidences of cardiovascular diseases, globally. The increasing prevalence of cardiovascular diseases is majorly driving the market growth. The key players are developing new novel drugs for cardiovascular diseases to meet the unmet needs is anticipated to create new opportunities for the market.

However, stringent government regulations associated with the research and development of drugs and the patent expiry of various blockbuster drugs are hindering market growth.

The Global Cardiovascular Drugs Market is segmented based on Drug Type, Disease Indications, Distribution Channel, and Geography.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Cardiovascular Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.

  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.

  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.

  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Market Dynamics


  • Rise in Number of Cardiovascular Disease

  • Increasing Geriatric Population

  • Existence of Numerous Novel Drugs


  • Stringent Regulations for Development of New Drugs


  • Advancement in R&D for Effective Drugs

  • Rising Healthcare Expenditure in Emerging Countries


  • Patent Expiry of Various Blockbuster Drugs

  • Side-Effects of Cardiovascular Drugs

Companies Mentioned

  • Abbott Laboratories

  • Astellas Pharma, Inc.

  • AstraZeneca plc

  • Amgen Inc

  • Aurobindo Pharma Ltd

  • Bayer AG

  • Baxter International Inc

  • Boehringer Ingelheim GmbH

  • Bristol-Myers Squibb Company

  • Cipla Ltd

  • Daiichi Sankyo Company Limited

  • Eli Lilly and Company

  • F.Hoffman-La Roche Ltd

  • Gilead Science, Inc

  • GlaxoSmithKline plc

  • Johnson & Johnson

  • Lupin Ltd

  • Merck & Co Inc

  • Medicure Inc

  • Novartis AG

  • Otsuka Pharmaceutical

  • Pfizer Inc

  • Sanofi S.A.

  • Sun Pharmaceutical Industries Ltd

  • Tadeka Pharmaceutical Company Limited

  • United Therapeutics Corporation

For more information about this report visit https://www.researchandmarkets.com/r/coldqd

View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005226/en/


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting